{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "34146504",
  "DateCompleted": {
    "Year": "2021",
    "Month": "06",
    "Day": "28"
  },
  "DateRevised": {
    "Year": "2021",
    "Month": "07",
    "Day": "23"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1016/S1474-4422(21)00168-X",
      "S1474-4422(21)00168-X"
    ],
    "Journal": {
      "ISSN": "1474-4465",
      "JournalIssue": {
        "Volume": "20",
        "Issue": "7",
        "PubDate": {
          "Year": "2021",
          "Month": "Jul"
        }
      },
      "Title": "The Lancet. Neurology",
      "ISOAbbreviation": "Lancet Neurol"
    },
    "ArticleTitle": "Could SARS-CoV-2 cause tauopathy?",
    "Pagination": {
      "StartPage": "506",
      "MedlinePgn": "506"
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Biochemistry, University of Colorado Boulder, Boulder, CO 80303, USA."
          }
        ],
        "LastName": "Pratt",
        "ForeName": "James",
        "Initials": "J"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Biochemistry, University of Colorado Boulder, Boulder, CO 80303, USA."
          }
        ],
        "LastName": "Lester",
        "ForeName": "Evan",
        "Initials": "E"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Biochemistry, University of Colorado Boulder, Boulder, CO 80303, USA; Howard Hughes Medical Institute, University of Colorado Boulder, Boulder, CO 80303, USA; BioFrontiers Institute, University of Colorado Boulder, Boulder, CO 80303, USA. Electronic address: roy.parker@colorado.edu."
          }
        ],
        "LastName": "Parker",
        "ForeName": "Roy",
        "Initials": "R"
      }
    ],
    "PublicationTypeList": [
      "Letter"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "England",
    "MedlineTA": "Lancet Neurol",
    "NlmUniqueID": "101139309",
    "ISSNLinking": "1474-4422"
  },
  "MeshHeadingList": [
    {
      "QualifierName": [
        "complications"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "pathogenicity"
      ],
      "DescriptorName": "SARS-CoV-2"
    },
    {
      "QualifierName": [
        "etiology",
        "immunology"
      ],
      "DescriptorName": "Tauopathies"
    }
  ],
  "CoiStatement": "RP reports being a co-founder and consultant for Faze Medicines. JP and EL declare no competing interests."
}